US AHRQ (Agency for Healthcare Research and Quality) study places drugs above surgery for GERD (gastroesophageal reflux disease) treatment
This article was originally published in Clinica
Executive Summary
In the first of a series of 10 studies comparing the effectiveness of medical treatments, researchers at the US Agency for Healthcare Research and Quality (AHRQ) have concluded that, in the treatment of gastroesophageal reflux disease (GERD), proton pump inhibitor drugs are as effective as surgery. The Medicare-mandated study - soon to be followed by studies on diabetes, breast imaging, depression and the off-label use of anti-psychotic drugs - took eight months in deciding that Nexium and Prilosec can be as effective at relieving symptoms as surgery.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.